Ubs Group Ag Rhythm Pharmaceuticals, Inc. Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
A detailed history of Ubs Group Ag transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 65,942 shares of RYTM stock, worth $3.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,942
Previous 171,565
61.56%
Holding current value
$3.27 Million
Previous $7.43 Million
63.58%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding RYTM
# of Institutions
178Shares Held
69.1MCall Options Held
467KPut Options Held
224K-
Primecap Management CO Pasadena, CA7.31MShares$363 Million0.22% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$335 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$318 Million3.49% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$302 Million3.77% of portfolio
-
Goldman Sachs Group Inc New York, NY5.29MShares$262 Million0.04% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.77B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...